CEP162

Across TCGA pan-cancer cohorts, CEP162 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CEP162’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where CEP162 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CEP162 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where CEP162 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEP162 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	−0.317	<.001	7	view →
LSCC	All	All	−0.216	<.001	6	view →
PDAC	Male	III,IV	−1.480	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

CEP162–LUAD

Open the LUAD breakdown →